The Integrity in Science Watch project of the Center for Science in the Public Interest has a weekly e-newsletter that includes cheers and jeers for certain aspects of health care journalism. This week's:
* Jeer to Alicia Chang of the Washington Post for failing to mention that the authors of a study supporting the off-label use of drug-eluting stents received funding from Cordis, Boston Scientific and Abbott Vascular, all manufacturers of drug-eluting stents.* Cheer to Stephanie Saul of the New York Times for noting that the American Heart Association, which has defended the cholesterol drug Vytorin in recent weeks, receives $2 million a year from Merck/Schering-Plough Pharmaceuticals, the joint venture that markets Vytorin.
Leave a comment.
Enter Comments, but.... I welcome comments but will delete those with product pitches, profanity, personal attacks or those from anyone who doesn't list what appears to be an actual e-mail address. We also don' t give medical advice and won't respond to any questions asking for it.